Cite
Enhanced in vivo antitumor efficacy of dual-functional peptide-modified docetaxel nanoparticles through tumor targeting and Hsp90 inhibition.
MLA
Jiang, Yao, et al. “Enhanced in Vivo Antitumor Efficacy of Dual-Functional Peptide-Modified Docetaxel Nanoparticles through Tumor Targeting and Hsp90 Inhibition.” Journal of Controlled Release, vol. 221, Jan. 2016, pp. 26–36. EBSCOhost, https://doi.org/10.1016/j.jconrel.2015.11.029.
APA
Jiang, Y., Yang, N., Zhang, H., Sun, B., Hou, C., Ji, C., Zheng, J., Liu, Y., & Zuo, P. (2016). Enhanced in vivo antitumor efficacy of dual-functional peptide-modified docetaxel nanoparticles through tumor targeting and Hsp90 inhibition. Journal of Controlled Release, 221, 26–36. https://doi.org/10.1016/j.jconrel.2015.11.029
Chicago
Jiang, Yao, Nan Yang, Huifeng Zhang, Bo Sun, Chunying Hou, Chao Ji, Ji Zheng, Yanyong Liu, and Pingping Zuo. 2016. “Enhanced in Vivo Antitumor Efficacy of Dual-Functional Peptide-Modified Docetaxel Nanoparticles through Tumor Targeting and Hsp90 Inhibition.” Journal of Controlled Release 221 (January): 26–36. doi:10.1016/j.jconrel.2015.11.029.